Ashley Chan

Ashley Chan joined the OncLive team as an assistant editor in 2025 after previously working on the CURE editorial team since 2023.

Email: achan@mjhlifesciences.com

Articles

Dr Chehrazi-Raffle on the Safety of Second-Line Tivozanib With/Without Nivolumab in RCC

June 13th 2025

Alexander Chehrazi-Raffle, MD, details safety data and the clinical implications of an analysis of second-line tivozanib for patients with metastatic RCC.

Real-World Data Confirm Efficacy of Axi-cel Across Patient-Related Factors in R/R LBCL

June 13th 2025

Although age did not affect real-world ORR or EFS with axi-cel in LBCL, an age of 65 years or older and cardiac comorbidities correlated with shorter OS.

Bexobrutideg Is Safe, Shows Early Efficacy in Relapsed/Refractory CLL

June 13th 2025

Bexobrutideg, a novel BTK degrader, has demonstrated preliminary efficacy and a tolerable safety profile in patients with relapsed/refractory CLL.

Dr Graham on Advancements in the Management of Ovarian Cancer

June 13th 2025

Deena M. Atieh Graham, MD, discusses notable shifts within the ovarian cancer landscape leading to better patient outcomes.

Dr Benjamin on Using Real-World Data to Bridge Knowledge Gaps in Urothelial Cancer Care

June 12th 2025

David J. Benjamin, MD, expands on real-world studies to help contextualize clinical trial data and inform treatment decisions in urothelial cancer.

Dr Hayne on Mitomycin/BCG as an Alternative to BCG Alone in Non–Muscle-Invasive Bladder Cancer

June 12th 2025

Dickon Hayne, MD, FRCS, MBBS, discusses the use of mitomycin plus BCG as a potential alternative to BCG alone in non–muscle-invasive bladder cancer.

Dr Daver on the Efficacy of Revumenib in NPM1+ Relapsed/Refractory AML

June 11th 2025

Naval G. Daver, MD, highlights the efficacy of revumenib for the treatment of patients with NPM1-mutant relapsed/refractory acute myeloid leukemia.

Olaparib/Temozolomide Fails to Meet PFS End Point in Previously Treated Advanced Uterine Leiomyosarcoma

June 11th 2025

Olaparib plus temozolomide was not superior to pazopanib or trabectedin for the treatment of patients with advanced uterine leiomyosarcoma.

Dr Sabari on c-MET as a Potential Biomarker of Response in EGFR Wild-Type NSCLC

June 11th 2025

Joshua Sabari, MD, explains the rationale behind targeting c-MET in nonsquamous EGFR wild-type advanced NSCLC.

Darolutamide/ADT Combo Delays Pain Progression and Enhances QOL in mHSPC

June 11th 2025

Alicia Morgans, MD, MPH, discusses findings from a QOL analysis of the ARANOTE trial, which evaluated darolutamide plus ADT in patients with mHSPC.

Dr Kalinsky on Evolving Roles for the CLEOPATRA and DESTINY-Breast09 Regimens in HER2+ Breast Cancer

June 10th 2025

Kevin Kalinsky, MD, MS, FASCO, discusses potential new roles for the CLEOPATRA and DESTINY-Breast09 regimens in the HER2-positive breast cancer paradigm.

Dr Schmidt on the Role of Minimally Invasive and Robotic Modalities in Bladder Cancer

June 9th 2025

Bogdana Schmidt, MD, MPH, discusses the role of minimally invasive and robotic strategies for the treatment of patients with bladder cancer.

OS Therapies Seeks RMAT Designation for OST-HER2 in Pediatric Lung-Metastatic Osteosarcoma

June 9th 2025

OS Therapies submits a RMAT designation request for OST-HER2 for the treatment of patients with pediatric lung-metastatic osteosarcoma.

FDA Lifts Partial Clinical Hold on Phase 3 Trial Evaluating IFx-2.0 in Advanced Merkel Cell Carcinoma

June 9th 2025

The FDA has lifted the partial clinical hold on a phase 3 study assessing IFx-2.0 in advanced Merkel cell carcinoma.

Curiosity and Compassion Propel Lung Cancer Pioneer Ramalingam to TIME100 Health 2025 List

June 9th 2025

Suresh S. Ramalingam, MD, FACP, FASCO, highlights his journey in the lung cancer field, leading up to his recognition on the TIME100 Health 2025 list.

RP1 Yields Responses in Deep/Visceral Lesions and Across Injected/Non-Injected Lesions in Advanced PD-1–Refractory Melanoma

June 6th 2025

RP1/nivolumab generated responses in deep/visceral lesions and in non-injected lesions in advanced PD-1–refractory melanoma.

Dr Tolaney on the Clinical Implications of First-Line T-DXd Plus Pertuzumab in HER2+ Breast Cancer

June 5th 2025

Sara M. Tolaney, MD, MPH, details the clinical implications for first-line T-DXd/pertuzumab for the treatment of patients with HER2-positive breast cancer.

Bispecific Antibodies Improve TTNT and Reshape R/R Follicular Lymphoma Management

June 5th 2025

Vivek Patel, MD, discusses the growing body of data supporting the use of bispecific antibodies in patients with relapsed/refractory follicular lymphoma.

Casdozokitug Plus Atezolizumab/Bevacizumab Yields Antitumor Activity in Unresectable, Advanced HCC

June 5th 2025

Daneng Li, MD, discusses the efficacy and safety findings of a casdozokitug-based regimen in unresectable, advanced HCC.

Dr O’Meara on the Evolving Role of ADCs in HER2+ Breast Cancer

June 4th 2025

Tess O’Meara, MD, highlights the role of antibody-drug conjugates for the treatment of patients with HER2-positive breast cancer.